Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 147

Sort by

Sort Order Select

Journal Articles

Feasibility of Utilizing a Virtual Health Assistant during Inpatient Reduced-Intensity Allogeneic Transplantation

Amar H Kelkar, Chantal Kerssens, Nicholas Groblewski, Dillon D Clancy, Hajime Uno, Corey Cutler, Danielle Sherman-Manhard, Robert J. Soiffer, Victor HS Wang, Gregory A Abel

Blood (2023) 142 (Supplement 1): 5104.

https://doi.org/10.1182/blood-2023-178619

Published: 2023

Journal Articles

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Blood (2023) 142 (Supplement 1): 1.

https://doi.org/10.1182/blood-2023-186963

Published: 2023

Journal Articles

Effective Prevention of Steroid-Requiring Chronic Graft-Vs.-Host Disease with B Cell Depletion: A Randomized, Placebo-Controlled Trial

Blood (2023) 142 (Supplement 1): 649.

https://doi.org/10.1182/blood-2023-180142

Published: 2023

Journal Articles

Impact of Clinical and Genetic Factors on Myelofibrosis Outcomes after Allogeneic Transplantation

Mahasweta Gooptu, Haesook T. Kim, Kaina Chen, Ann Mullally, Joseph Antin, Corey Cutler, Amar H Kelkar, John Koreth, Roman M. Shapiro, Robert J. Soiffer, Daniel J. DeAngelo, Jacqueline S. Garcia, Marlise R. Luskin, Richard M Stone, Martha Wadleigh, Eric S. Winer, R. Coleman Lindsley, Vincent Ho

Blood (2023) 142 (Supplement 1): 4978.

https://doi.org/10.1182/blood-2023-178684

Published: 2023

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia - Retrospective Dual-Center Study

Blood (2023) 142 (Supplement 1): 4979.

https://doi.org/10.1182/blood-2023-179962

Published: 2023

Journal Articles

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Blood (2023) 142 (Supplement 1): 2246.

https://doi.org/10.1182/blood-2023-185315

Published: 2023

Journal Articles

Post-Transplant T Cell Clonotype Diversity Is Associated with Survival in Patients with TP53-Mutated Acute Myeloid Leukemia

Blood (2023) 142 (Supplement 1): 2176.

https://doi.org/10.1182/blood-2023-181863

Published: 2023

Journal Articles

Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk

Blood (2023) 142 (Supplement 1): 3618.

https://doi.org/10.1182/blood-2023-185220

Published: 2023

Journal Articles

Out-of-Pocket Costs and Financial Hardship Among Participants of the BMT CTN 1102 Study

Christopher T. Su, Wael Saber, Aasthaa Bansal, Li Li, Ryotaro Nakamura, Corey Cutler, Bart L. Scott, Lindsey R Sangaralingham, Viengneesee Thao, Joshua Roth, Winona Wright, Lotte Steuten, Deborah Mattila, Scott D Ramsey

Blood (2023) 142 (Supplement 1): 262.

https://doi.org/10.1182/blood-2023-187218

Published: 2023

Journal Articles

Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Blood (2023) 141 (24): 2932–2943.

https://doi.org/10.1182/blood.2022019107

Published: 2023

Includes: Supplemental data

Journal Articles

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

Blood (2023) 141 (15): 1884–1888.

https://doi.org/10.1182/blood.2022017686

Published: 2023

Includes: Supplemental data

Journal Articles

Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial

Blood (2022) 140 (Supplement 1): 2135–2136.

https://doi.org/10.1182/blood-2022-166996

Published: 2022

Journal Articles

Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309

Annie Im, Daniel Wolff, Corey Cutler, Robert Zeiser, Nirav N. Shah, Ming Tony Tan, Jaime Sanz, Haris Ali, Giuseppe Milone, Arjun D. Law, Domenico Russo, Eva-Maria Wagner, Olga Ivanova, Kevin Hou, Maureen Bleam, Rodica Morariu-Zamfir, Steven Z Pavletic

Blood (2022) 140 (Supplement 1): 1870–1871.

https://doi.org/10.1182/blood-2022-169605

Published: 2022

Journal Articles

The Prevalence and Effects of Frailty in Chronic Graft-Versus-Host Disease

Nahid Rashid, Mukta Arora, Paul A. Carpenter, Amin M Alousi, Betty K. Hamilton, Joseph Pidala, Lynn E. Onstad, Corey Cutler, Mary E.D. Flowers, Sally Arai, Smita Bhatia, Stephanie J. Lee

Blood (2022) 140 (Supplement 1): 10519–10520.

https://doi.org/10.1182/blood-2022-167901

Published: 2022

Journal Articles

Impact of Exercise on the Complications of Corticosteroids in Patients with Graft-Versus-Host Disease Following Allogeneic Cell Transplantation: The Restart Trial

Rebekah L. Wilson, Dong-Woo Kang, Paola Gonzalo-Encabo, Cami Christopher, Amber Normann, Danny Nguyen, Mary K. Norris, Marilyn J. Hammer, Corey Cutler, Christina M. Dieli-Conwright

Blood (2022) 140 (Supplement 1): 4782–4783.

https://doi.org/10.1182/blood-2022-167175

Published: 2022

Journal Articles

Allogeneic Stem Cell Cryopreservation Is Associated with Equivalent Survival and Relapse Rates with Lower Rate of Severe Chronic Gvhd

Katie Maurer, Haesook T. Kim, Heather Garrity, Carol Reynolds, Deborah Liney, Augustine Weber, Joseph H. Antin, Corey Cutler, Jerome Ritz, John Koreth, Roman M. Shapiro, Rizwan Romee, Vincent Ho, Mahasweta Gooptu, Catherine J. Wu, Sarah Nikiforow, Robert J. Soiffer

Blood (2022) 140 (Supplement 1): 4804–4805.

https://doi.org/10.1182/blood-2022-162663

Published: 2022

Journal Articles

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Blood (2021) 138 (22): 2278–2289.

https://doi.org/10.1182/blood.2021012021

Published: 2021

Includes: Supplemental data

Journal Articles

Health-Related Quality of Life in a Biologic Assignment Trial of Reduced Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome

Rachel Cusatis, Michael Martens, Ryotaro Nakamura, Corey Cutler, Wael Saber, Stephanie J. Lee, Brent R. Logan, Bronwen E. Shaw, Mary M. Horowitz, Kathryn E Flynn

Blood (2021) 138 (Supplement 1): 421.

https://doi.org/10.1182/blood-2021-147514

Published: 2021

Journal Articles

Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease

Blood (2021) 138 (Supplement 1): 264.

https://doi.org/10.1182/blood-2021-148343

Published: 2021

Journal Articles

Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101

Blood (2021) 138 (Supplement 1): 3956.

https://doi.org/10.1182/blood-2021-145527

Published: 2021

NARROW

Feasibility of Utilizing a Virtual Health Assistant during Inpatient Reduced-Intensity Allogeneic Transplantation

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Effective Prevention of Steroid-Requiring Chronic Graft-Vs.-Host Disease with B Cell Depletion: A Randomized, Placebo-Controlled Trial

Impact of Clinical and Genetic Factors on Myelofibrosis Outcomes after Allogeneic Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia - Retrospective Dual-Center Study

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Post-Transplant T Cell Clonotype Diversity Is Associated with Survival in Patients with TP53-Mutated Acute Myeloid Leukemia

Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk

Out-of-Pocket Costs and Financial Hardship Among Participants of the BMT CTN 1102 Study

Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial

Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309

The Prevalence and Effects of Frailty in Chronic Graft-Versus-Host Disease

Impact of Exercise on the Complications of Corticosteroids in Patients with Graft-Versus-Host Disease Following Allogeneic Cell Transplantation: The Restart Trial

Allogeneic Stem Cell Cryopreservation Is Associated with Equivalent Survival and Relapse Rates with Lower Rate of Severe Chronic Gvhd

Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study

Health-Related Quality of Life in a Biologic Assignment Trial of Reduced Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome

Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease

Impact of Center Experience with Donor Type and Treatment Platform on Outcomes: A Secondary Analysis BMT CTN 1101

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only